Hamish McAllister-Williams

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2378330/publications.pdf

Version: 2024-02-01

75 papers

4,187 citations

172457 29 h-index 63 g-index

75 all docs 75 docs citations

75 times ranked 5232 citing authors

#	Article	IF	CITATIONS
1	Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2016, 30, 495-553.	4.0	755
2	Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology, 2015, 29, 459-525.	4.0	528
3	Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology, 2008, 22, 343-396.	4.0	437
4	Assessment and management of agitation in psychiatry: Expert consensus. World Journal of Biological Psychiatry, 2016, 17, 86-128.	2.6	204
5	British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. Journal of Psychopharmacology, 2017, 31, 519-552.	4.0	166
6	Mood and neuropsychological function in depression: the role of corticosteroids and serotonin. Psychological Medicine, 1998, 28, 573-584.	4.5	162
7	The identification, assessment and management of difficult-to-treat depression: An international consensus statement. Journal of Affective Disorders, 2020, 267, 264-282.	4.1	133
8	Birth weight of infants after maternal exposure to typical and atypical antipsychotics: Prospective comparison study. British Journal of Psychiatry, 2008, 192, 333-337.	2.8	130
9	Assessing cortisol and dehydroepiandrosterone (DHEA) in saliva: effects of collection method. Journal of Psychopharmacology, 2006, 20, 643-649.	4.0	101
10	Sleep and circadian rhythm disturbance in bipolar disorder. Psychological Medicine, 2017, 47, 1678-1689.	4.5	84
11	Rapid tranquillisation: Time for a reappraisal of options for parenteral therapy. British Journal of Psychiatry, 2002, 180, 485-489.	2.8	82
12	Ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT): a multicentre, double-blind, randomised, parallel-group, superiority trial. Lancet Psychiatry,the, 2017, 4, 365-377.	7.4	82
13	Effects of DHEA administration on episodic memory, cortisol and mood in healthy young men: a double-blind, placebo-controlled study. Psychopharmacology, 2006, 188, 541-551.	3.1	77
14	The use of the EEG in measuring therapeutic drug action: focus on depression and antidepressants. Journal of Psychopharmacology, 2011, 25, 1175-1191.	4.0	66
15	Effects of a single dose of cortisol on the neural correlates of episodic memory and error processing in healthy volunteers. Psychopharmacology, 2003, 167, 431-442.	3.1	63
16	Effects of tryptophan depletion on brain potential correlates of episodic memory retrieval. Psychopharmacology, 2002, 160, 434-442.	3.1	60
17	Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition. British Journal of Psychiatry, 2019, 214, 27-35.	2.8	54
18	Early life trauma, depression and the glucocorticoid receptor gene – an epigenetic perspective. Psychological Medicine, 2015, 45, 3393-3410.	4.5	51

#	Article	IF	Citations
19	Hematological Effects of Valproate in Psychiatric Patients. Journal of Clinical Psychopharmacology, 2010, 30, 282-285.	1.4	49
20	The use of antidepressants in clinical practice: focus on agomelatine. Human Psychopharmacology, 2010, 25, 95-102.	1.5	42
21	Bipolar and psychotic disorders in elite athletes: a narrative review. British Journal of Sports Medicine, 2019, 53, 746-753.	6.7	42
22	Neurocognitive intra-individual variability in mood disorders: effects on attentional response time distributions. Psychological Medicine, 2015, 45, 2985-2997.	4.5	38
23	5-Hydroxytryptamine receptor function in humans is reduced by acute administration of hydrocortisone. Psychopharmacology, 1998, 139, 243-250.	3.1	34
24	Lack of effect of tryptophan depletion on the loudness dependency of auditory event related potentials in healthy volunteers. Biological Psychology, 2004, 65, 137-145.	2.2	34
25	Lithium in bipolar and other affective disorders: prescribing practice in the UK. Journal of Psychopharmacology, 2010, 24, 1739-1746.	4.0	34
26	The association between sleep and cognitive abnormalities in bipolar disorder. Psychological Medicine, 2020, 50, 125-132.	4.5	33
27	Effects of repeated cortisol administration on brain potential correlates of episodic memory retrieval. Psychopharmacology, 2002, 160, 74-83.	3.1	31
28	Corticosterone modulation of somatodendritic 5-HT1A receptor function in mice. Journal of Psychopharmacology, 2002, 16, 245-252.	4.0	30
29	Do antidepressants work? A commentary on "Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration" by Kirsch et al. Evidence-Based Mental Health, 2008, 11 , 66 - 68 .	4.5	30
30	Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial. Lancet Psychiatry, the, 2016, 3, 117-127.	7.4	30
31	Metyrapone in treatment-resistant depression. Therapeutic Advances in Psychopharmacology, 2012, 2, 139-149.	2.7	29
32	The interrelationship between attentional and executive deficits in major depressive disorder. Acta Psychiatrica Scandinavica, 2016, 134, 73-82.	4.5	29
33	Multiple-therapy-resistant major depressive disorder: a clinically important concept. British Journal of Psychiatry, 2018, 212, 274-278.	2.8	28
34	Repeated cortisol administration attenuates the EEG response to buspirone in healthy volunteers: evidence for desensitization of the 5-HT1 A autoreceptor. Journal of Psychopharmacology, 2007, 21, 826-832.	4.0	27
35	EEG effects of buspirone and pindolol: a method of examining 5-HT1A receptor function in humans. Psychopharmacology, 2003, 166, 284-293.	3.1	26
36	Cortisol awakening response and spatial working memory in man: a Uâ€shaped relationship. Human Psychopharmacology, 2014, 29, 295-298.	1.5	25

#	Article	IF	CITATIONS
37	The temperature dependence of high-threshold calcium channel currents recorded from adult rat dorsal raphe neurones. Neuropharmacology, 1995, 34, 1479-1490.	4.1	21
38	Testâ€"retest reliability and task order effects of emotional cognitive tests in healthy subjects. Cognition and Emotion, 2016, 30, 1247-1259.	2.0	21
39	The effects of vagus nerve stimulation on the course and outcomes of patients with bipolar disorder in a treatment-resistant depressive episode: a 5-year prospective registry. International Journal of Bipolar Disorders, 2020, 8, 13.	2.2	20
40	Acute effects of venlafaxine and paroxetine on serotonergic transmission in human volunteers. Psychopharmacology, 1999, 146, 194-198.	3.1	19
41	Reconceptualising treatment-resistant depression as difficult-to-treat depression. Lancet Psychiatry,the, 2021, 8, 14-15.	7.4	19
42	Analysing UK clinicians' understanding of cognitive symptoms in major depression: A survey of primary care physicians and psychiatrists. Journal of Affective Disorders, 2017, 207, 346-352.	4.1	18
43	A study of the neural correlates of episodic memory and HPA axis status in drug-free depressed patients and healthy controls. Journal of Psychiatric Research, 2007, 41, 295-304.	3.1	17
44	Managing inadequate antidepressant response in depressive illness. British Medical Bulletin, 2015, 115, 183-201.	6.9	17
45	Graduate mental health worker case management of depression in UK primary care: a pilot study. British Journal of General Practice, 2007, 57, 880-885.	1.4	17
46	Effects of dexamethasone on neuroendocrine and psychological responses to L-tryptophan infusion. Psychopharmacology, 1999, 143, 64-71.	3.1	14
47	Altered hippocampal function in major depression despite intact structure and resting perfusion. Psychological Medicine, 2016, 46, 2157-2168.	4.5	14
48	The modulation of calcium channel currents recorded from adult rat dorsal raphe neurones by 5-HT1A receptor or direct G-protein activation. Neuropharmacology, 1995, 34, 1491-1506.	4.1	13
49	Effects of adrenalectomy on 8-OH-DPAT induced hypothermia in mice. Psychopharmacology, 1999, 142, 73-77.	3.1	12
50	Somatodendritic 5-hydroxytryptamine _{1A} (5-HT _{1A}) autoreceptor function in major depression as assessed using the shift in electroencephalographic frequency spectrum with buspirone. Psychological Medicine, 2014, 44, 767-777.	4.5	12
51	Cognitive function after electroconvulsive therapy for depression: relationship to clinical response. Psychological Medicine, 2021, 51, 1647-1656.	4.5	12
52	Study protocol for the randomised controlled trial: Ketamine augmentation of ECT to improve outcomes in depression (Ketamine-ECT study). BMC Psychiatry, 2015, 15, 257.	2.6	11
53	Assessment for vagus nerve stimulation in patients with difficult-to-treat depression: a model from the Newcastle Regional Affective Disorders Service (RADS). Journal of Affective Disorders, 2021, 280, 315-318.	4.1	11
54	Schizophrenia and increased risk of cardiovascular disease. American Heart Journal, 2006, 151, e13.	2.7	10

#	Article	IF	CITATIONS
55	A case of pancytopenia. Journal of Psychopharmacology, 2006, 20, 690-692.	4.0	9
56	A naturalistic evaluation and audit database of agomelatine: clinical outcome at 12Âweeks. Acta Psychiatrica Scandinavica, 2013, 128, 203-211.	4.5	9
57	Esketamine and the Need for a New Type of Registry for Drugs With Abuse Potential. American Journal of Psychiatry, 2019, 176, 966-966.	7.2	9
58	When depression is difficult to treat. European Neuropsychopharmacology, 2022, 56, 89-91.	0.7	9
59	Frontal haemodynamic responses in depression and the effect of electroconvulsive therapy. Journal of Psychopharmacology, 2019, 33, 1003-1014.	4.0	8
60	Effect of low-dose acute tryptophan depletion on the specificity of autobiographical memory in healthy subjects with a family history of depression. Psychopharmacology, 2012, 222, 285-292.	3.1	7
61	Connectivity guided theta burst transcranial magnetic stimulation versus repetitive transcranial magnetic stimulation for treatment-resistant moderate to severe depression: study protocol for a randomised double-blind controlled trial (BRIGhTMIND). BMJ Open, 2020, 10, e038430.	1.9	7
62	Effects of Antidepressant Drugs on Electroencephalography Alpha Power: Importance of Study Duration. Biological Psychiatry, 2008, 64, e5-e6.	1.3	5
63	Serotonin syndrome following introduction of venlafaxine following withdrawal of phenelzine: implications for drug washout periods. Therapeutic Advances in Psychopharmacology, 2011, 1, 125-127.	2.7	4
64	Intramuscular haloperidol-promethazine sedates violent or agitated patients more quickly than intramuscular lorazepam. Evidence-Based Mental Health, 2005, 8, 7-7.	4.5	3
65	Connectivity-Guided Theta Burst Transcranial Magnetic Stimulation Versus Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Moderate to Severe Depression: Magnetic Resonance Imaging Protocol and SARS-CoV-2–Induced Changes for a Randomized Double-blind Controlled Trial. IMIR Research Protocols, 2022, 11, e31925.	1.0	3
66	Exacerbation of migraine with paroxetine: Case report. Human Psychopharmacology, 1995, 10, 349-350.	1.5	2
67	Prescribing of venlafaxine and dosulepin in primary care. Journal of Psychopharmacology, 2006, 20, 868-868.	4.0	2
68	Vegetarian psychotropics: a survey of psychotropic medications suitable for vegetarians. Human Psychopharmacology, 2009, 24, 248-249.	1.5	2
69	Study protocol for a randomised placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment resistant bipolar depression (the PAX-BD study). BMC Psychiatry, 2021, 21, 334.	2.6	2
70	Noradrenaline – the forgotten amine?. Journal of Psychopharmacology, 2013, 27, 657-658.	4.0	1
71	The  difficult-to-treat depression' and the  response paradigm' models: Implications and relevance to patient management. Australian and New Zealand Journal of Psychiatry, 2021, 55, 824-825.	2.3	1
72	Managing the aftermath of mania - Newcastle, 2 September 2005: Consensus Meeting Statement. Journal of Psychopharmacology, 2006, 20, 51-54.	4.0	O

#	Article	IF	CITATIONS
73	Commentary on STAR*D: a summary and UK perspective. Journal of Psychopharmacology, 2009, 23, 615-617.	4.0	0
74	Review: clinically important differences between antidepressants. Evidence-Based Mental Health, 2009, 12, 107-107.	4.5	0
75	Author's reply to Letter to the Editor. Journal of Psychopharmacology, 2012, 26, 1164-1164.	4.0	0